Zhongsheng Pharmaceutical: The first participant has been enrolled in the Phase III clinical trial of RAY1225 injection, a drug for lowering blood sugar levels.

Zongsheng Pharmaceuticals announced that the first participant in two Phase III clinical trials of the innovative peptide drug RAY1225 injection, independently developed by its holding subsidiary Zongsheng Ruichuang, has been enrolled and dosed. RAY1225 injection is a peptide drug with global independent intellectual property rights, and has the potential for long-lasting effects with injections every two weeks. Zongsheng Ruichuang will continue to advance the Phase III clinical trials of RAY1225 injection, striving to complete the relevant research as soon as possible and apply for drug marketing approval.